Despite the lack of evidence on safety or efficacy, many clinicians offer whole body therapeutic hypothermia to infants with mild hypoxic ischaemic encephalopathy, and even to those without any encephalopathy. Such a wide variation in clinical practice within the NHS not only leads to poorer outcomes and may harm infants who would have otherwise done well, but masks improvements in obstetric care and increase litigations. The COMET trial will establish the safety and efficacy of whole-body hypothermia for mild hypoxic ischaemic ...

GO TO STUDY

Myeloma (MM) is an incurable blood cancer. While survival has substantially improved over the last decade, there is still huge variability in clinical outcomes between patients. The current approach to drug development assumes that all patients respond similarly to a given drug despite the fact that only a third of MM patients are eligible to take part in therapeutic clinical trials. Within the NHS, the current treatment approach to MM means that all patients receive the same treatments according ...

GO TO STUDY

The main purpose of the trial is to determine when the most beneficial time for people to start or restart a DOAC after their head injury is. People will be asked to start the medication either 1 week or 4 weeks after their head injury. This will be randomly assigned by a computer. They will then be followed closely for 12 weeks and any major bleeding events or a blood clots (thrombotic events) such as a stroke or heart attack ...

GO TO STUDY

This is a Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability, and safety of frexalimab, SAR442970, and rilzabrutinib in participants from 16 to 75 years of age with biopsy-proven primary FSGS or MCD, with eGFR ≥ 45 mL/min/1.73 m2, and UPCR ≥ 3 g/g at screening, who have demonstrated at least partial response (≥ 40% UPCR reduction) to at least one previous immunosuppressive therapy. The purpose of this study is to measure the change in proteinuria and its impact ...

GO TO STUDY

Transcatheter aortic valve implantation (TAVI) is a key-hole technique to replace a faulty (narrowed and/or leaking) aortic heart valve. The replacement aortic valve is delivered to the heart through tubes inserted in a main artery (usually the artery in the groin). Over the past 15 years TAVI has rapidly grown and has taken over from open-heart surgery (surgical aortic valve replacement (SAVR)) to become the most commonly used technique for aortic heart valve replacement. Although TAVI is a safe and effective ...

GO TO STUDY

Background Sciatica is a term used to describe pain in the leg, but it is actually caused by an irritation of the small nerves in the lower back. One in four people with sciatica also report weakness in the affected leg. In my recent work, 85% of people coming to a hospital appointment for sciatica reported leg weakness, but our hospital tests detected weakness in only 34% of them. This means that many people have a problem that their health ...

GO TO STUDY

This study will test if a new software program called EpiPredict can predict which biologic therapy might work best for treating Crohn’s disease (CD). This study will include about 378 participants from 6 countries in Europe, and about 98 participants in the United Kingdom (UK). EpiPredict will predict how well two biologics for CD (vedolizumab and ustekinumab) will work. Both vedolizumab and ustekinumab are approved for use in people with CD as part of their usual care. This study is testing if ...

GO TO STUDY

CRYSTAL is an observational study whereby participants will attend one 4 ½ -hour visit at the Division of Cardiovascular Medicine,University of Oxford at the John Radcliffe Hospital in Oxford,with the option to split the study visit over two days for convenience. Participants will be recruited from the ALSPAC cohort (G0 mothers cohort),75 will have had a hypertensive pregnancy and 75 will have had a normotensive pregnancy. At time of follow-up,they will be 30-35 years post pregnancy. Of the G0 cohort,2237 ...

GO TO STUDY

VISTA is a multicentre,double-blinded,randomised Phase I/IIa trial. Patients diagnosed with resectable OAC and recommended to have neoadjuvant chemotherapy will be offered entry into the trial. The Phase I Safety Lead-in will treat 8x participants with ITOP1 A/B,and Phase II will randomise 52x participants (3:1) to receive either ITOP1 or placebo (sterile 0.9% normal saline). Patients will initially be asked to consent to undergo a pre-screening test to determine their HLA type. Only patients that match to at least one of ...

GO TO STUDY

Our aim is to see if palliative long-term abdominal drains (LTADs) result in better quality of life in patients with fluid in the belly due to liver scarring (cirrhosis), compared with current standard of care. The liver can be damaged by excessive alcohol and viral infections. If liver damage continues this scarring leads to permanent damage. It causes a painful buildup of fluid in the abdomen (ascites). Drugs can treat this, but may stop working, leading to ...

GO TO STUDY